Mania in a Patient With Multiple Myeloma After Using Bortezomib

Huinan Jiang, Rong Hu, Miao Miao, Bin Wu, Zhuogang Liu


Multiple myeloma (MM) is caused by a clonal proliferation of malignant plasma cells and ranks the second most frequent malignancy of hematology. Despite emerging intensive therapies including new agents and high-dose treatment with stem-cell transplantation, MM still remains an incurable neoplastic disease. Bortezomib was the first proteasome inhibitor (PI) which can improve response rates and overall survival in both newly diagnosed and recurrent MM patients with few adverse effects. The patient was a 61-year-old woman with MM who suffered from mania after initially receiving chemotherapy regimen of PTD (bortezomib, thalidomide, dexamethasone). The regimen was forced to stop due to the severe adverse effect. Then the symptoms were relieved and the patient was given VAD (vincristine, adriamycin, dexamethasone) regimen, and mania was never performed again. It has not been shown that bortezomib can lead to mania in MM patients in the introduction of the drug. Timely detection, immediately stopping related drugs and treating the primary disease actively are key steps for improvement. Poor psychosocial state is another crucial factor which ought to be taken into account in the prevention and treatment of mania occurrence.

J Med Cases. 2014;5(12):627-630


Mania; Multiple myeloma; Bortezomib; Drug-related side effects and adverse reactions

Full Text: HTML PDF

Browse  Journals  


Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics


World Journal of Oncology

Gastroenterology Research

Journal of Hematology


Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity


Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research


Journal of Neurology Research

International Journal of Clinical Pediatrics



Journal of Medical Cases, monthly, ISSN 1923-4155 (print), 1923-4163 (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)

This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website:   editorial contact:
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

Disclaimer: The views and opinions expressed in the published articles are those of the authors and do not necessarily reflect the views or opinions of the editors and Elmer Press Inc. This website is provided for medical research and informational purposes only and does not constitute any medical advice or professional services. The information provided in this journal should not be used for diagnosis and treatment, those seeking medical advice should always consult with a licensed physician.